Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stephanie L. Verwys"'
Autor:
Alison J. Moskowitz, Susan J. McCall, Joachim Yahalom, Matthew J. Matasar, Kurt S. Bantilan, Zhigang Zhang, Craig H. Moskowitz, Debra A. Goldman, Stephanie L. Verwys, Gunjan L. Shah
Publikováno v:
British Journal of Haematology. 175:440-447
We aimed to identify risk factors that predict functional imaging (FI) response to salvage chemotherapy and evaluate outcomes following autologous stem cell transplant (ASCT) in primary refractory Hodgkin Lymphoma (HL). From 1 October 1994 to 10 July
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534d1246b5bab9310b1847fc4c773cb7
https://doi.org/10.1111/bjh.14245
https://doi.org/10.1111/bjh.14245
Autor:
Stephanie L. Verwys, Anas Younes, Audrey Hamilton, Gianna N. McArthur, Zhigang Zhang, Steven M. Horwitz, Paul M. Barr, Joachim Yahalom, Craig H. Moskowitz, Susan J. McCall, Matthew J. Matasar, Philip Caron, Andrew D. Zelenetz, Maria Lia Palomba, John F. Gerecitano, Ariela Noy, Jonathan W. Friedberg, Joanna C. Yang, Alexandra G. Jacob, Carla Casulo, Louis S. Constine, April Chiu, Paul A. Hamlin, Anita Kumar, Carol S. Portlock, David J. Straus, Nicholas VanderEls, Alison J. Moskowitz, Pamela Drullinsky, Heiko Schöder
Publikováno v:
Blood. 128(11)
This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aee9320201aedaa42a5e92976ae9045
https://pubmed.ncbi.nlm.nih.gov/27458003
https://pubmed.ncbi.nlm.nih.gov/27458003
Autor:
Heiko Schöder, Amanda I. Courtien, Craig S. Sauter, Shoshana T. Miller, Craig H. Moskowitz, Susan J. McCall, Pamela Jo Harris, Stephanie L. Verwys, Anas Younes, Matthew J. Matasar
Publikováno v:
Blood. 128:4198-4198
Background: In the post-rituximab era, half the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response with standard salvage therapy, and are thus ineligible to proceed to consol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6972fb9984ef16a69ba59e2e53d6ec7
https://doi.org/10.1182/blood.v128.22.4198.4198
https://doi.org/10.1182/blood.v128.22.4198.4198
Autor:
Alison J. Moskowitz, Gunjan L. Shah, Joachim Yahalom, Matthew J. Matasar, Craig H. Moskowitz, Kurt S. Bantilan, Stephanie L. Verwys, Susan J. McCall
Publikováno v:
Blood. 126:520-520
Introduction: Limited information exists on the best treatment strategy for Primary Refractory (ref) Hodgkin Lymphoma (HL). For the past 20 years, we have treated patients (pts) on sequential ifosfamide, carboplatin, etoposide (ICE)-based clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1c99df669134226fe8ef33d2dad91f7
https://doi.org/10.1182/blood.v126.23.520.520
https://doi.org/10.1182/blood.v126.23.520.520
Autor:
Carol S. Portlock, Stephanie L. Verwys, Andrew D. Zelenetz, Zhigang Zhang, John F. Gerecitano, Craig H. Moskowitz, Heiko Schöder, Alison J. Moskowitz, Lia Palomba, Alexandra G. Jacob, Audrey Hamilton, Anita Kumar, Susan J. McCall, Paul A. Hamlin, Ariela Noy, Philip Caron, Anas Younes, David J. Straus, Joachim Yahalom, Matthew J. Matasar, Pamela Drullinsky, Steven M. Horwitz
Publikováno v:
Memorial Sloan Kettering Cancer Center
Background: Brentuximab vedotin has not been previously studied in combination with combined modality therapy for the frontline treatment of early stage Hodgkin lymphoma. We designed a pilot study to assess the safety and early efficacy of four cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c3dc7ce17bc32aa46373bf34c2e8bb
https://synapse.mskcc.org/synapse/works/71447
https://synapse.mskcc.org/synapse/works/71447
